Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Hanlon

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
Plos Medicine|April 7, 2025
Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse eventsHeather Wightman, Elaine Butterly, Lili Wei, et al.
Annals of Family Medicine|March 11, 2020
Assessing Risks of Polypharmacy Involving Medications With Anticholinergic PropertiesPeter Hanlon, Terence J Quinn, Katie I Gallacher, et al.
The Lancet Regional Health. Europe|December 17, 2021
Child maltreatment and incident mental disorders in middle and older ages: a retrospective UK Biobank cohort studyJohn M Macpherson, Stuart R Gray, Patrick Ip, et al.
Ageing Research Reviews|July 18, 2024
Frailty and socioeconomic position: A systematic review of observational studiesPeter Hanlon, Marina Politis, Heather Wightman, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 21, 2025
Frailty in Adults with Chronic Kidney Disease and Validation of the Kidney Failure Risk Equation in Frailty Sub-GroupsHeather Walker, Juan-Jesus Carrero, Michael K Sullivan, et al.
Plos Medicine|May 8, 2020
Multimorbidity, mortality, and HbA1c in type 2 diabetes: A cohort study with UK and Taiwanese cohortsJason I Chiang, Peter Hanlon, Tsai-Chung Li, et al.
Journal of Primary Care & Community Health|December 14, 2023
Multimorbidity and Blood Pressure Control in Patients Attending Primary Care in CanadaTu N Nguyen, Sumeet Kalia, Peter Hanlon, et al.
Plos Medicine|June 6, 2023
Treatment effect modification due to comorbidity: Individual participant data meta-analyses of 120 randomised controlled trialsPeter Hanlon, Elaine W Butterly, Anoop Sv Shah, et al.
Plos Medicine|January 17, 2023
Comorbidity and health-related quality of life in people with a chronic medical condition in randomised clinical trials: An individual participant data meta-analysisElaine W Butterly, Peter Hanlon, Anoop S V Shah, et al.
BMC Medicine|November 27, 2025
Assessing the representativeness of trials of Sodium-glucose Cotransporter-2 inhibitors in type 2 diabetes: a comparison of individual-level trial data and people newly prescribed treatment in a Welsh routine care databasePeter Hanlon, Heather Wightman, Michael Sullivan, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Plos Medicine|April 7, 2025
Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: An individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse eventsHeather Wightman, Elaine Butterly, Lili Wei, et al.
Annals of Family Medicine|March 11, 2020
Assessing Risks of Polypharmacy Involving Medications With Anticholinergic PropertiesPeter Hanlon, Terence J Quinn, Katie I Gallacher, et al.
The Lancet Regional Health. Europe|December 17, 2021
Child maltreatment and incident mental disorders in middle and older ages: a retrospective UK Biobank cohort studyJohn M Macpherson, Stuart R Gray, Patrick Ip, et al.
Ageing Research Reviews|July 18, 2024
Frailty and socioeconomic position: A systematic review of observational studiesPeter Hanlon, Marina Politis, Heather Wightman, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 21, 2025
Frailty in Adults with Chronic Kidney Disease and Validation of the Kidney Failure Risk Equation in Frailty Sub-GroupsHeather Walker, Juan-Jesus Carrero, Michael K Sullivan, et al.
Plos Medicine|May 8, 2020
Multimorbidity, mortality, and HbA1c in type 2 diabetes: A cohort study with UK and Taiwanese cohortsJason I Chiang, Peter Hanlon, Tsai-Chung Li, et al.
Journal of Primary Care & Community Health|December 14, 2023
Multimorbidity and Blood Pressure Control in Patients Attending Primary Care in CanadaTu N Nguyen, Sumeet Kalia, Peter Hanlon, et al.
Plos Medicine|June 6, 2023
Treatment effect modification due to comorbidity: Individual participant data meta-analyses of 120 randomised controlled trialsPeter Hanlon, Elaine W Butterly, Anoop Sv Shah, et al.
Plos Medicine|January 17, 2023
Comorbidity and health-related quality of life in people with a chronic medical condition in randomised clinical trials: An individual participant data meta-analysisElaine W Butterly, Peter Hanlon, Anoop S V Shah, et al.
BMC Medicine|November 27, 2025
Assessing the representativeness of trials of Sodium-glucose Cotransporter-2 inhibitors in type 2 diabetes: a comparison of individual-level trial data and people newly prescribed treatment in a Welsh routine care databasePeter Hanlon, Heather Wightman, Michael Sullivan, et al.
Pageof 9